The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 13, 2018
Filed:
Mar. 23, 2015
Applicant:
National Jewish Health, Denver, CO (US);
Inventor:
Milene Saavedra, Denver, CO (US);
Assignee:
National Jewish Health, Denver, CO (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12P 19/34 (2006.01); G01N 33/537 (2006.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01); G06F 19/24 (2011.01); G16H 50/30 (2018.01); G06F 19/00 (2018.01);
U.S. Cl.
CPC ...
G01N 33/537 (2013.01); C12Q 1/6883 (2013.01); G01N 33/68 (2013.01); G01N 33/6893 (2013.01); G06F 19/00 (2013.01); G06F 19/24 (2013.01); G06F 19/70 (2013.01); G16H 50/30 (2018.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); G01N 2333/54 (2013.01); G01N 2333/705 (2013.01); G01N 2333/70503 (2013.01); G01N 2333/70535 (2013.01); G01N 2333/70596 (2013.01); G01N 2333/924 (2013.01); G01N 2333/96486 (2013.01); G01N 2400/40 (2013.01); G01N 2800/122 (2013.01); G01N 2800/125 (2013.01); G01N 2800/127 (2013.01); G01N 2800/50 (2013.01);
Abstract
The present invention is related to a method for determining pulmonary disease progression severity in a subject having cystic fibrosis and treating the subject according to the severity. The method comprises obtaining a whole blood sample from the subject; detecting the mRNA expression level of each of the following genes: TLR2, ADAM9, PLXND1, CD163, CD36, CD64, CSPG2, IL32, HPSE, HCA112; determining the severity of the pulmonary disease progression based on the subject's combined mRNA expression level of the genes; and treating the subject.